The HERG or the human Ether-a-go-go-Related Gene is a gene that codes for the protein known as Kv11.1, the alpha subunit of a potassium ion channel. It is used in the contribution to the activity of the heart. Its channels moderate the repolarizing current in the cardiac action potential, this helps in the beating of the heart. The HERG assessments have now became one of the priority requirements from the regulatory agencies before the submission of the investigational new drug. Some of the assays of the HERG screening are like manual/ automatic patch clamp assay, HERG radio ligand binding assay, fluorescence polarization assay, microelectrode array. In the automatic patch clamp assay the HERG current is recorded in different concentrations. It is done before and after the exposure of it to the test compounds. Then the IC50 values are determined by the technique called dose formulation analysis. Likewise, the other assays are also performed as per their respective norms. The HERG screening poses various advantages like it has the presence of channel which acts as the target for class III antiarrhythmic drugs like amiodarone, it prolongs the action potential and also reduces the risk of the re-entrant arrythmias. It can be used in the treatment of the diseases like Cancer, recurrent epileptic seizures, Schizophrenia by playing the role of the diagnostic marker.
COVID-19 Scenario Analysis:
At the early phase of COVID-19 pandemic, there was no availability of specific diagnostic tests to detect the disease in patients. Alternative diagnostic tests were used initially but were not much effective. This unavailability of specific COVID-19 diagnostic tests presented lucrative opportunities for diagnostic manufacturers to introduce their COVID-19 diagnostic kits. Many leading players as well as some start-ups from various countries utilized this opportunity and introduced COVID-19 diagnostics kits into local as well as global market. These players achieved edge over other diagnostics players capitalizing the opportunity from demand for COVID-19 diagnostic tests, which, in turn, helps them in maintaining their revenues in such a crisis.
Top impacting factors: Market Scenario Analysis, Trends, Drivers, Impact Analysis
Increase in prevalence of heart diseases and rise in number of patients of heart disorders are expected to drive the growth of the market. Rise in the number of the R&D in the field for the new product launches also helps to drive the growth of the market. Moreover, increase in the approvals of the new drug entities is also expected to aid in the growth of the market. Increase in demand for the drug formulation and the development to cure the diseases or disorders also helps to boost the growth of the market. Furthermore, increasing challenges in developing biotechnological or the pharmaceutical product based on the application is helping to build opportunities for the growth of the HERG screening market.
However, the high cost of the HERG screening products is expected to hamper the growth of the HERG screening market.
New product launches to flourish the market:
In July 2017, the acquisition of the Discover X, was announced by the Eurofins Scientific. This is a main agent in the drug discovery products and services from target identification and lead discovery to the preclinical and beyond.
In March 2020, Charles River Laboratories made the partnership with Deciphex. They now work together to develop deep learning enabled tools to support accelerated pathology analytics.
Surge in the usage of the HERG screening products:
The increase in the prevalence of the heart diseases and the drug developments to treat the disease may increase the usage of the HERG screening products. Moreover, the decrease in the cost till the affordable rates may help to surge the usage of the HERG screening products.
Key benefits of the report:
- This study presents the analytical depiction of the global HERG screening industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global HERG screening market share.
- The current market is quantitatively analyzed to highlight the global HERG screening market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the HERG screening market.
- The report provides a detailed global HERG screening market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the HERG screening market research report:
- What are the leading market players active in the HERG screening market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the HERG screening market?
- What are the projections for the future that would help in taking further strategic steps?
HERG Screening Market Report Highlights
By Product Type
By Ion Channel
Key Market Players
B’SYS GmbH, AstraZeneca plc, Eurofins-Cerep SA, ChanTest Corporation, Cambridge Bioscience Ltd, AVIVA Biosciences, ABR-Affinity BioReagents, Inc., ChemAxon, Molecular Devices LLC, Caliper, Aurora Biomed Inc., Cellular Dynamics International, Charles River Laboratories, Inc., Others., Abcam PLC, A PerkinElmer Company, Aureus Sciences